Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Incyte Corporation
Related studies linked through entity extraction aliases.
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease
- Status
- RECRUITING
- Phase
- PHASE1
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE3
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
- Status
- RECRUITING
- Phase
- PHASE1
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Status
- RECRUITING
- Phase
- PHASE1
PH 2 Pemigatinib in SDH-deficient GIST
- Status
- RECRUITING
- Phase
- PHASE2
ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE2
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Amping up With PemJAK
- Status
- RECRUITING
- Phase
- PHASE2
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2